NEO1

Across TCGA pan-cancer cohorts, NEO1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NEO1 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher NEO1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NEO1 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

HNSC, LUAD, and GBM are the cancer types where NEO1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.588	0.866	.001	38	view →
LUAD	DFS	Tertile	II,III,IV	0.700	0.979	.008	9	view →
GBM	OS	Quartile	All	0.561	0.235	.014	5	view →
UCEC	OS	Median	All	0.914	0.984	.040	2	view →
CCRCC	DFS	Median	II,III,IV	0.806	0.346	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NEO1–HNSC (OS)

Open the HNSC breakdown →